Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyVentura County Gonal-F Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Gonal-F (follitropin alfa) prior authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Gonal-F (follitropin alfa) injection used to treat infertility in qualifying female and male patients. It specifies eligible diagnoses, required clinical documentation, fertility-specialist involvement, dosing, monitoring, and authorization duration.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGonal-F (follitropin alfa) prior authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateMay 2, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit the authorization request with the infertility evaluation and treatment plan, planned Gonal-F dose and duration, qualified fertility-specialist treatment, and applicable laboratory and prior-treatment documentation.
    SourceLink
    POLICY UPDATE CHANGES

    The policy replaced the prior Gonal-F definition with a follitropin alfa definition and added dosing information for ovulation induction and spermatogenesis induction.

    2Covered patient populations
    300 units/dayMaximum ovulation-induction dose
    35 daysOvulation-induction maximum duration
    18 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Spermatogenesis-induction maximum duration
    12 or 6 monthsInfertility definition threshold

    Coverage Criteria

    Female Infertility

    Covered for female patients when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following infertility definitions applies

      • Women aged 35 and younger: failure to conceive after no less than 12 months of unprotected intercourse, or inability to carry a pregnancy to term.

        CHSC 1374.55(b); see VCHCP Medical Policy: Infertility: Treatment of.

      • Women older than 35: failure to conceive after no less than 6 months of unprotected intercourse, or inability to carry a pregnancy to term.

        CHSC 1374.55(b); see VCHCP Medical Policy: Infertility: Treatment of.

    • Diagnosis of infertility due to anovulation or poor ovarian reserve.
    • The prior authorization request includes a detailed description of the patient's infertility evaluation and treatment plan, including the Gonal F dose and duration of treatment.

      Required in the prior authorization request.

    • Treatment is performed by a qualified fertility specialist.
    • Documentation of the patient's thyroid and adrenal function.
    • Documentation of the patient's prior response to fertility treatments, if applicable.

    Male Infertility

    Covered for male patients when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of infertility due to hypogonadotropic hypogonadism.
    • The prior authorization request includes a detailed description of the patient's infertility evaluation and treatment plan, including the Gonal F dose and duration of treatment.

      Required in the prior authorization request.

    • Treatment is performed by a qualified fertility specialist.
    • Documentation of the patient's prior response to testosterone replacement therapy, if applicable.

    Ovulation Induction

    Ovulation induction dosing and authorization parameters:

    ALL of the following

    • Administer subcutaneously at an initial dose of 75 units daily for 14 days in the first cycle.
    • After 14 days, incremental dose adjustments of up to 37.5 units may be considered based on ovarian response; further dose increases of the same magnitude may be made every 7 days if necessary.

      Maximum dose: 300 units daily.

    • Continue treatment until follicular growth and/or serum estradiol levels indicate an adequate ovarian response.
    • If response to follitropin is appropriate, administer human chorionic gonadotropin (hCG) 1 day after the last dose to induce final oocyte maturation and ovulation.
    • Follow current clinical practice to reduce the risk of ovarian hyperstimulation syndrome.

    Spermatogenesis Induction

    Spermatogenesis induction dosing and authorization parameters:

    ALL of the following

    • Begin therapy with human chorionic gonadotropin (hCG) pretreatment until serum testosterone is in the normal range.
    • After hCG pretreatment, initiate follitropin alfa at 150 units subcutaneously 3 times weekly, with hCG administered 3 times weekly.
    • Continue treatment with the lowest dose needed to induce spermatogenesis.

      Maximum follitropin alfa dose: 300 units 3 times weekly.

    • Treatment may be continued for up to 18 months.

    Coverage Parameters

    Infertility duration for women aged 35 and younger
    PopulationWomen aged 35 and younger
    Minimum periodNo less than 12 months of unprotected intercourse
    Alternative criterionInability to carry a pregnancy to term
    Infertility duration for women older than 35
    PopulationWomen older than 35
    Minimum periodNo less than 6 months of unprotected intercourse
    Alternative criterionInability to carry a pregnancy to term

    Authorization and Documentation Requirements

    Prior Authorization

    Qualifying Diagnosis Required

    Prior authorization is required for Gonal-F when treatment is requested for a qualifying infertility diagnosis. The diagnosis must be infertility due to anovulation or poor ovarian reserve in female patients, or hypogonadotropic hypogonadism in male patients.

    • Female qualifying diagnoses: infertility due to anovulation or poor ovarian reserve.
    • Male qualifying diagnosis: infertility due to hypogonadotropic hypogonadism.
    • For women aged 35 and younger, infertility includes failure to conceive after at least 12 months of unprotected intercourse or inability to carry a pregnancy to term.
    • For women older than 35, infertility includes failure to conceive after at least 6 months of unprotected intercourse or inability to carry a pregnancy to term.
    Prior Authorization

    Required Prior Authorization Submission

    Submit a complete prior authorization request with the clinical information needed to establish medical necessity and support safe use and monitoring of Gonal-F.

    Clinical Background

    Follitropin alfa is a recombinant human follicle-stimulating hormone (FSH) preparation used to stimulate ovarian follicular growth in women who do not have primary ovarian failure and to stimulate spermatogenesis in men with hypogonadotropic hypogonadism. FSH supports normal follicular growth, maturation, gonadal steroid production, and spermatogenesis. Gonal-F is supplied as a subcutaneous injection and requires monitoring of treatment response.

    Infertility Definitions

    Definition of infertility in women aged 35 and younger
    PopulationWomen aged 35 and younger
    Conception criterionFailure to conceive after no less than 12 months of unprotected intercourse
    Pregnancy criterionInability to carry a pregnancy to term
    Definition of infertility in women older than 35
    PopulationWomen older than 35
    Conception criterionFailure to conceive after no less than 6 months of unprotected intercourse
    Pregnancy criterion
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGonal-F (follitropin alfa) prior authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateMay 2, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit the authorization request with the infertility evaluation and treatment plan, planned Gonal-F dose and duration, qualified fertility-specialist treatment, and applicable laboratory and prior-treatment documentation.
    SourceLink
    On This Page
    Coverage CriteriaCoverage ParametersAuthorization and Documentation RequirementsClinical BackgroundInfertility Definitions
  1. Therapy should generally not exceed 35 days.
  2. Approve Gonal F for one year or until conception.
  3. Ovulation-induction maximum dose
    TreatmentOvulation induction with subcutaneous Gonal-F
    Maximum dose300 units daily
    Dose adjustmentIncreases of up to 37.5 units may be made after 14 days, with further increases of the same magnitude every 7 days if needed
    Ovulation-induction general maximum duration
    TreatmentOvulation induction
    General maximum durationTherapy should not exceed 35 days in general
    Initial cycle75 units daily for 14 days before dose adjustment based on ovarian response
    Spermatogenesis-induction maximum dose
    TreatmentSpermatogenesis induction with subcutaneous follitropin alfa
    Maximum dose300 units 3 times weekly
    Usual starting dose150 units 3 times weekly after hCG pretreatment until serum testosterone is in the normal range
    Spermatogenesis-induction maximum duration
    TreatmentSpermatogenesis induction
    Maximum authorization durationUp to 18 months
    Treatment conditionBegin with hCG pretreatment until serum testosterone is in the normal range
    • Detailed infertility evaluation and treatment plan.
    • Planned Gonal-F dose and duration of treatment.
    • Applicable laboratory and prior-treatment documentation.
    • Qualified fertility-specialist information and confirmation of specialist involvement.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Prior Authorization

    Qualified Fertility Specialist Required

    Treatment must be performed by a qualified fertility specialist. Include documentation identifying the specialist and confirming specialist involvement in the patient's treatment.

    • Qualified fertility-specialist participation is required for both female and male treatment requests.
    Denial Risk

    Nonqualifying Diagnosis May Result in Denial

    Requests may be denied when the documented infertility diagnosis does not meet the Plan's qualifying criteria.

    • Female diagnosis must be infertility due to anovulation or poor ovarian reserve.
    • Male diagnosis must be infertility due to hypogonadotropic hypogonadism.
    • The Plan's infertility definition includes the applicable duration of unsuccessful unprotected intercourse or inability to carry a pregnancy to term.
    Denial Risk

    Incomplete Clinical Documentation May Result in Denial

    Incomplete documentation may result in denial or delay of the prior authorization request. Ensure that all required clinical information is submitted with the request.

    • Infertility evaluation and treatment plan.
    • Gonal-F dose and treatment duration.
    • Female thyroid and adrenal function, when applicable.
    • Prior response to fertility treatment or testosterone replacement therapy, when applicable.
    • Qualified fertility-specialist documentation.
    Inability to carry a pregnancy to term